Detalles de la búsqueda
1.
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Nat Immunol
; 23(9): 1379-1392, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002648
2.
HER2 mutation as an emerging target in advanced breast cancer.
Cancer Sci
; 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38715247
3.
Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.
Int J Mol Sci
; 23(23)2022 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36498861
4.
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9).
Breast Cancer Res Treat
; 190(1): 103-109, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34453206
5.
Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists.
Int J Med Sci
; 18(10): 2235-2238, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859532
6.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Int J Med Sci
; 18(10): 2245-2250, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33859534
7.
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience.
Breast J
; 27(4): 359-362, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33677841
8.
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
J Cell Physiol
; 235(11): 7900-7910, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943171
9.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31330065
10.
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives.
Int J Mol Sci
; 21(10)2020 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32429381
11.
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
J Cell Physiol
; 234(6): 7708-7717, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536609
12.
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
J Transl Med
; 17(1): 99, 2019 03 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-30917841
13.
Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.
Breast J
; 25(3): 444-449, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30932296
14.
GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.
J Cell Physiol
; 233(2): 1396-1401, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28542798
15.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
J Cell Physiol
; 233(3): 2313-2323, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28710865
16.
Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
J Transl Med
; 16(1): 247, 2018 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30180862
17.
Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
J Transl Med
; 16(1): 22, 2018 02 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29402328
18.
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
J Transl Med
; 16(1): 129, 2018 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29769125
19.
Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer.
J Cell Physiol
; 232(8): 2246-2252, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987320
20.
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
J Cell Physiol
; 232(6): 1571-1578, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27861874